Amylyx Pharmaceuticals Statistics
Total Valuation
AMLX has a market cap or net worth of $4.05 billion. The enterprise value is $3.29 billion.
| Market Cap | 4.05B |
| Enterprise Value | 3.29B |
Important Dates
The last earnings date was Thursday, November 5, 2026, before market open.
| Earnings Date | Nov 5, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
AMLX has 128.56 million shares outstanding. The number of shares has increased by 33.83% in one year.
| Current Share Class | 128.56M |
| Shares Outstanding | 128.56M |
| Shares Change (YoY) | +33.83% |
| Shares Change (QoQ) | +6.97% |
| Owned by Insiders (%) | 5.91% |
| Owned by Institutions (%) | 85.73% |
| Float | 112.63M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | 478.40 |
| PB Ratio | 5.27 |
| P/TBV Ratio | 5.39 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 26.81, with a Debt / Equity ratio of 0.01.
| Current Ratio | 26.81 |
| Quick Ratio | 26.54 |
| Debt / Equity | 0.01 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -30.06% and return on invested capital (ROIC) is -20.03%.
| Return on Equity (ROE) | -30.06% |
| Return on Assets (ROA) | -19.11% |
| Return on Invested Capital (ROIC) | -20.03% |
| Return on Capital Employed (ROCE) | -23.19% |
| Weighted Average Cost of Capital (WACC) | 3.81% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$1.20M |
| Employee Count | 136 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
In the past 12 months, AMLX has paid $46,000 in taxes.
| Income Tax | 46,000 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +159.77% in the last 52 weeks. The beta is -0.08, so AMLX's price volatility has been lower than the market average.
| Beta (5Y) | -0.08 |
| 52-Week Price Change | +159.77% |
| 50-Day Moving Average | 29.81 |
| 200-Day Moving Average | 20.64 |
| Relative Strength Index (RSI) | 62.14 |
| Average Volume (20 Days) | 1,277,749 |
Short Selling Information
The latest short interest is 13.25 million, so 10.31% of the outstanding shares have been sold short.
| Short Interest | 13.25M |
| Short Previous Month | 12.67M |
| Short % of Shares Out | 10.31% |
| Short % of Float | 11.76% |
| Short Ratio (days to cover) | 9.49 |
Income Statement
| Revenue | n/a |
| Gross Profit | -92.43M |
| Operating Income | -175.73M |
| Pretax Income | -163.15M |
| Net Income | -163.20M |
| EBITDA | -175.45M |
| EBIT | -175.73M |
| Earnings Per Share (EPS) | -$1.45 |
Balance Sheet
The company has $768.13 million in cash and $4.94 million in debt, with a net cash position of $763.19 million or $5.94 per share.
| Cash & Cash Equivalents | 768.13M |
| Total Debt | 4.94M |
| Net Cash | 763.19M |
| Net Cash Per Share | $5.94 |
| Equity (Book Value) | 753.74M |
| Book Value Per Share | 5.86 |
| Working Capital | 749.81M |
Cash Flow
In the last 12 months, operating cash flow was -$129.88 million and capital expenditures -$141,000, giving a free cash flow of -$130.02 million.
| Operating Cash Flow | -129.88M |
| Capital Expenditures | -141,000 |
| Depreciation & Amortization | 282,000 |
| Net Borrowing | 544.24M |
| Free Cash Flow | -130.02M |
| FCF Per Share | -$1.01 |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
AMLX does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | -33.83% |
| Shareholder Yield | -33.83% |
| Earnings Yield | -4.60% |
| FCF Yield | -3.20% |
Analyst Forecast
The average price target for AMLX is $43.00, which is 36.51% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $43.00 |
| Price Target Difference | 36.51% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 12 |
| Revenue Growth Forecast (3Y) | n/a |
| EPS Growth Forecast (3Y) | n/a |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
| Graham Formula Value | n/a |
| Graham Formula Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 2 |